AKT1 and triple-negative breast carcinoma: Recently, Fu et al. [19] reported that dual blockade of EGFR/PI3K/AKT and NOTCH signaling has the potential to decrease resistance and thus may gain clinical efficacy in triple-negative breast cancer.